Mutation of SMARCA4 (BRG1), the ATPase of BAF (mSWI/SNF) and PBAF complexes, contributes to a range of malignancies and neurologic disorders. Unfortunately, the effects of SMARCA4 missense mutations have remained uncertain. Here we show that SMARCA4 cancer missense mutations target conserved ATPase surfaces and disrupt the mechanochemical cycle of remodeling. We find that heterozygous expression of mutants alters the open chromatin landscape at thousands of sites across the genome. Loss of DNA accessibility does not directly overlap with Polycomb accumulation, but is enriched in 'A compartments' at active enhancers, which lose H3K27ac but not H3K4me1. Affected positions include hundreds of sites identified as superenhancers in many tissues. Dominant-negative mutation induces pro-oncogenic expression changes, including increased expression of Myc and its target genes. Together, our data suggest that disruption of enhancer accessibility represents a key source of altered function in disorders with SMARCA4 mutations in a wide variety of tissues.
Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Prague, Czech Republic. 6 Howard Hughes Medical Institute, Chevy Chase, MD, USA. H. Courtney Hodges and Benjamin Z. Stanton contributed equally to this work. *e-mail: zhaok@nhlbi.nih.gov; crabtree@stanford.edu E pigenetic deregulation is widely regarded as a hallmark of cancer and certain neurologic disorders. Among the most frequently mutated chromatin regulatory complexes are polymorphic BAF (mSWI/SNF) and PBAF complexes 1, 2 . These ATP-dependent chromatin remodelers are mutated in ~20% of cancers 3, 4 , with mutations in specific subunits contributing to specific cancers 1 . For cancers such as malignant rhabdoid tumors (MRTs) 5, 6 and synovial sarcoma (SS) 7 , tissue-specific alterations of individual BAF subunits arise in ~100% of cases, and repair of these defects in cell-culture models leads to loss of both transformation and proliferation. Moreover, animal models and epigenomic studies of human patients have provided extensive evidence that these complexes are major tumor suppressors 8 whose mutations contribute to transformation in many cell types 9 .
In MRTs and SS, the ability of BAF complexes to oppose Polycomb repression proximal to transcription start sites (TSSs) is central to their role in these malignancies. In MRTs, biallelic loss of SMARCB1 induces abnormal subunit composition 10, 11 and impairs opposition to Polycomb silencing at the tumor-suppressor gene CDKN2A (INK4A, refs [12] [13] [14] ). Silencing of CDKN2A in turn impairs cell-cycle control, thereby inducing rapid transformation and proliferation without genomic instability 15, 16 . In SS, the protein product of the SS18-SSX gene fusion 17 incorporates into BAF complexes, leading to reduction of the Polycomb-associated silencing mark H3K27me3 near the TSSs of oncogenic genes such as EGR1 (ref. 18 ) and SOX2 (ref. 7 ). For both MRTs and SS, changes of Polycomb occupancy at TSSs across the genome coincide with transformation, and in both cases, these changes are reversible by exogenous expression or repair of the underlying BAF defect 7, 19, 20 .
Recent studies in BAF-deficient cancer models have revealed alterations at enhancers distal to TSSs, which contain transcription factor binding sites. In MRT cells, loss of SMARCB1 induces characteristic changes of the permissive mark H3K27ac at tissue-restricted enhancers, but largely preserves the function of superenhancers 11 . Moreover, in animal models of colon cancer, loss of the BAF subunit Arid1a leads to impaired enhancer function, with deregulation of APC-beta-catenin signaling pathways 21 . Similar results have been observed in mouse embryonic fibroblasts 22 . In mouse embryonic stem (ES) cells (mESCs), topoisomerase inhibition leads to impairment of BAF's ability to generate accessible sites over the genome, indicating that these factors work in tandem to generate accessibility 23 . Thus, emerging evidence suggests that altered function at enhancers arises upon loss of BAF activity, in addition to Polycomb deregulation.
SMARCA4, a central ATPase of BAF complexes, is the most frequently mutated Snf2-like gene in human cancer 1 and has been identified as a major tumor suppressor in pan-cancer studies 1, 8 . Unlike the tissue-restricted alterations of SMARCB1 and SS18, loss-of-function mutations of SMARCA4 are enriched in diverse cancer types, contributing to a range of cancers including those of the lung [24] [25] [26] , ovaries [27] [28] [29] , skin 4, 30 , thoracic sarcomas 31 , and lymphomas 32, 33 . SMARCA4 inactivation is especially common in small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) 27, 28 . Dual biallelic inactivation of SMARCA4 and the related ATPase SMARCA2 are highly specific to SCCOHT 29 , thus indicating that complete loss of BAF and PBAF ATP-dependent chromatin-remodeling activity is an essential feature of this malignancy.
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In contrast to the precise, reproducible genetic changes observed in SCCOHT, the impacts of diverse heterozygous SMARCA4 mutations distributed across many cancer types have remained uncertain and controversial. Recently, we showed that deletion and heterozygous cancer mutations of the SMARCA4 ATPase induce genomewide accumulation of Polycomb repressive complexes 1 and 2 (PRC1 and PRC2) at bivalent TSSs across the genome 34 . However, it has remained uncertain how these mutations impair SMARCA4's fundamental mechanisms to promote malignancy. Here we show that these mutations induce divergent effects on SMARCA4 dynamics in living cells, but the impairment of normal function through distinct mechanisms results in convergent changes of the DNA-accessibility landscape at enhancers and superenhancers used in many cell types.
Results
Heterozygous mutation of SMARCA4 is a common feature of many cancers. To assess the frequency of heterozygous SMARCA4 missense mutations in cancer, we performed a pan-cancer analysis of human tumor sequencing studies, including The Cancer Genome Atlas (TCGA) whole-exome studies 35 and MSK-IMPACT 36 targeted sequencing studies in which SMARCA4 mutations and deletions were observed. We eliminated samples with only silent mutations and no other changes and furthermore restricted our analysis to samples in which copy-number analysis had also been performed, leaving 927 human tumor samples. Analysis of the overall genetic state of SMARCA4 in these samples ( Fig. 1a ) shows that most samples (56.5%, 524 of 927) contain a single allele affected by missense mutations without other aberrations. In contrast, other major tumor suppressors, such as ARID1A (20.9%, 370 of 1,773, P < 2.2 × 10 -16 ) and RB1 (14.5%, 155 of 1,066, P < 2.2 × 10 -16 ), have significantly lower fractions of samples with only single missense mutations ( Fig. 1b) .
To assess whether samples with missense mutations had comparable levels of expression as nonmutated samples, we analyzed RNA sequencing (RNA-seq) data from TCGA studies. We found that samples with single missense mutations had comparable levels of SMARCA4 expression ( Fig. 1c ), consistent with heterozygous mutation. Our analysis shows that heterozygous mutation is the most common mode of disruption to many different cancers in which SMARCA4 is mutated.
Cancer mutations of SMARCA4 induce distinct dynamic defects of remodeling in living cells. Frequent cancer mutations within the SMARCA4 ATPase domain have provided a rich source of alleles to probe the mechanisms of these proteins. To gain insight into their mechanisms, we generated a homology model of SMARCA4 bound to a nucleosome based on the high degree of sequence homology with structures of related Snf2 homologs from diverse organisms, including Saccharomyces cerevisiae Snf2 (PDB 5X0X) 37 , Thermothelomyces thermophila Snf2 (PDB 5HZR) 38 , and S. cerevisiae Chd1 (PDB 3MWY) 39 (full details of the construction of this homology model are provided in Methods, and 3D coordinates of mouse and human SMARCA4 homology models are provided in PDB format as supplemental data). Our model revealed that frequently mutated positions of SMARCA4 lie in functionally important surfaces, such as the DNA groove between the N-and C-terminal ATPase domains and the ATP cleft ( Fig. 2a and Supplementary Fig. 1 ).
We analyzed the positions of all cancer missense mutations on cBioPortal 40 ; we found that most (56%, n = 575) SMARCA4 mutations affected the bipartite ATPase domain (Fig. 2b) . By calculating the solvent-accessible surface area for each position, we found that frequently mutated positions in cancer are distributed in structurally diverse locations of the domain. Some mutation hotspots, such as T910, are expected to affect residues that are buried or have little exposed surface area ( Fig. 2c ). As disruption of folding or thermodynamic stability would be expected to impair function in a nonspecific manner, we turned our focus to residues that were frequently mutated at important surfaces, specifically, the ATP cleft and DNA groove ( Supplementary Fig. 1 ).
We hypothesized that alterations of these positions might induce distinct dynamic defects, because they occur at surfaces with unique molecular functions. We therefore generated a targeted library of alterations at these sites, including p.G782S, p.G784E, p.K785R, p.T786I, p.T786N, p.P811R, p.L815P, p.Y860H, p.E861K, p.D881G, p.E882D, p.E882K, and p.H884N (numbered according to the human protein product; UniProt P51532). We expressed these mutations as C-terminal GFP fusions and performed a screen for dynamic defects using fluorescence recovery after photobleaching (FRAP) following lentiviral transduction in 293T cells ( Fig. 2d-f ). Compared to wild-type SMARCA4-GFP, we found that ATP-cleft mutants consistently showed slower FRAP recovery ( Fig. 2f ). In contrast, DNA-groove mutants consistently showed fast recovery times compared to wild type (Fig. 2f ). These data are consistent with a model whereby DNA-groove mutants disrupt engagement of immobile chromatin, but ATP-cleft mutants disrupt ATPdependent release from immobile chromatin ( Fig. 2g ). This model is supported by previous observations that the ATPase activity of SMARCA4 and orthologs is DNA stimulated 41, 42 , as ATP hydrolysis requires prior interaction with nucleic acid substrate.
To validate the observed dynamics from this screen, we generated a transgenic mouse expressing SMARCA4 fused to the fluorescent protein Dendra2 (ref. 43 ), comparable to GFP ( Supplementary  Fig. 2 ). This fusion did not affect protein function, and homozygous SMARCA4-Dendra2 mice were bred and deposited at Jackson Laboratories for cryopreservation (stock #27901). In mESCs, SMARCA4-Dendra2 displays a high degree of stability (with stability half-life comparable to the cell doubling time) and shows FRAP dynamic properties identical to those of SMARCA4-GFP expressed via lentiviral transduction ( Supplementary Fig. 3 ), confirming the validity of our approach. Interestingly, we found that the delayed FRAP recovery of ATPase mutants arises during interphase but not mitosis, when BAF is largely excluded from condensed mitotic chromosomes (Supplementary Figs. 3 and 4), consistent with previous observations that SMARCA4 is phosphorylated during mitosis 44 . Our results reveal a convergence between tumor sequencing studies, molecular structure, and live-cell dynamics.
Cancer mutants induce convergent effects on the chromatin landscape. Because ATP-cleft and DNA-groove mutants induced opposing dynamic effects, we anticipated that they might give rise to distinct effects on the chromatin landscape, even in a heterozygous setting frequently observed in cancer. To probe the functional impacts of commonly mutated positions, we used mESCs as a convenient model to investigate the conserved effects following Smarca4 disruption. These cells are advantageous for fundamental studies, owing to the clonal nature of their growth, lack of genetic heterogeneity, negligible mutation load, and the availability of genetic tools such as conditional knockouts. ES cells also do not express the alternate BAF ATPase SMARCA2 (BRM), permitting us to exclude confounding effects from this homologous gene. Using a conditional Smarca4-knockout mESC line 45 , we rescued Smarca4 deletion with lentiviral expression of wild-type SMARCA4-GFP fusion and either wild-type or mutant SMARCA4 tagged with V5 (SMARCA4-V5). Resulting cells had expression levels of SMARCA4 equivalent to those of endogenous protein, as previously described ( Supplementary Fig. 4 in ref. 34 ). As a control, we compared results from these cells to those from similarly prepared cells expressing wild-type SMARCA4-V5 instead of a mutant. This strategy allowed us to observe the effects of mutation in a setting that mimics heterozygous mutation present in human cancers.
We assayed transposase-accessible chromatin using sequencing (ATAC-seq) 46 to identify locations where SMARCA4 mutants Articles NATUre STrUcTUrAL & MoLecULAr BIoLogy altered genomic DNA accessibility. To our surprise, we observed that heterozygous mutant cells showed highly correlated changes across the genome compared to wild-type cells ( Fig. 3a-c ). Sites with accessibility losses associated with mutants were generally stronger and more frequent than sites that gained accessibility. We assigned sites into one of three categories: decreased, unchanged, and increased (definitions in Methods). We analyzed the genomic annotations of sites that decreased accessibility and discovered that relative to unchanged sites, these sites were highly enriched at noncoding regions, particularly introns and intergenic regions ( Fig. 3d) .
We furthermore analyzed a dataset of 111 public chromatin immunoprecipitation sequencing (ChIP-seq) studies in wild-type mESCs, which permitted us to investigate the association of factors with gains or losses of accessibility in our current study. Lasso multivariate regression for all of our mutant ATAC-seq datasets revealed a robust and consistent association with several factors related to enhancers in mESCs, including Lsd1, Smc1, H3K27ac, Oct4, and Brd4 ( Fig. 3e ).
Because these changes were highly correlated across all mutants, we conclude that these mutants surprisingly have convergent effects on the DNA-accessibility landscape. We therefore focused the remainder of our analysis on G784E, which is located at the ATP-binding cleft in the Walker A motif and makes direct contact with ATP ( Fig. 2a ). We found that ATAC accessibility sites were enriched in wild-type cells with ChIP density of Smarcc1, a core subunit of BAF complexes ( Fig. 3f-h ). Furthermore, sites with decreased accessibility following expression of G784E SMARCA4 (n = 8,805) were highly enriched with H3K4me1 in wild-type cells (Fig. 3f ), a mark frequently found at enhancers. Sites that increased accessibility (n = 2,887) typically had low levels of Lsd1 ( Fig. 3h) , an H3K4 demethylase involved in enhancer decommissioning 47 . These results suggest that the gains of accessibility following expression of mutant SMARCA4 depend on the absence of Lsd1. Unchanged sites (n = 24,656) generally contained mixed amounts of these factors and include many regulatory sites, such as housekeeping TSSs. 
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Polycomb accumulation does not reduce local accessibility.
Polycomb repression is thought to be mediated by altering DNA accessibility 48 . We investigated the relationship between changes of accessibility and Polycomb accumulation that occurs over the genome. We examined direct overlap between changes of Polycomb occupancy (reflected by ChIP-seq of Ring1b, a core catalytic subunit of PRC1) and DNA accessibility (reflected by ATAC-seq) in two settings: Smarca4 conditional biallelic deletion 23, 34 and heterozygous ATPase mutation (G784E). Although both conditional knockout and heterozygous mutation result in strong and characteristic accumulation of PRC1 and PRC2 at bivalent TSSs over the genome 34 , we observed no direct relationship between increases of Polycomb and altered accessibility ( Fig. 4a-d ). This observation did not arise because of nonoverlap of peaks, as ATAC-seq and Ring1b ChIP peaks had high enrichment at both TSSs and enhancers ( Supplementary Fig. 5 ), and changes at individual sites were highly reproducible ( Supplementary Fig. 6 ). We confirmed this result by performing ATAC-seq following conditional knockout of Ring1b in cells lacking Ring1a (ref. 49 Buried and surface mutations are frequent sites of mutations, including the ATP-binding cleft, DNA-binding groove, and other sites with unknown function. d, FRAP recovery curves for SMARCA4-GFP mutants of the ATP-binding cleft show slow photobleaching recovery. e, FRAP recovery curves for SMARCA4-GFP mutants of the DNA-binding groove show fast photobleaching recovery. Curves for wild-type (WT) controls (dotted) are the same for all plots in d,e, from ten cells prepared from n = 2 cell-culture replicates. f, Positions found within the ATP-binding cleft or DNA-binding groove show similar FRAP recovery kinetics. Two-sample KS test compared to WT, *P < 0.05; **P < 0.01; ***P < 0.001. Plotted values are mean t 1/2 recovery times, error bars are s.e.m. from ten cells from n = 2 cellculture replicates. g, Model of how mutations affecting SMARCA4 surface alter dynamic engagement of chromatin. DNA-binding-groove mutants impair engagement with DNA, whereas ATP-binding-cleft mutants impair ATP hydrolysis, which may be required for transition to a mobile state.
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catalytic subunits of PRC1, and found that global accessibility at TSSs showed few changes. Instead, altered accessibility at enhancers was far more apparent ( Fig. 4e , P < 2.2 × 10 -16 ). Therefore, the increased occupancy of PRC1 we previously described at TSSs following SMARCA4 inactivation 34 does not directly coincide with altered accessibility. We conclude that DNA-accessibility changes are distinct from the accumulation of Polycomb complexes at bivalent TSSs. Our results challenge longstanding in vitro models of the repressive mechanisms associated with Polycomb factors.
Epigenomic alterations to enhancer identity. We next sought to compare the effects of heterozygous SMARCA4 G784E on accessibility at enhancers and TSSs. Accessibility was broadly unaffected at TSSs but was reduced at annotated mESC enhancers 50 (Fig. 5a,b ; Changes are uncorrelated with changes between wild-type cell-culture replicates. c, Heat map showing the 2,000 genome-wide sites with the highest variance across datasets. All mutants show a similar trend of altered accessibility across these sites. d, Genomic annotation enrichment for decreased sites across mutant ATAC-seq datasets. Decreased-accessibility sites are enriched at noncoding regions such as introns and intergenic regions. e, Lasso multivariate regression identifies a consistent set of features associated with positive or negative changes of accessibility in mutants compared to wild type. Features associated with altered accessibility include several factors and marks associated with enhancers. f, Characterization of ATAC-seq in sites with decreased accessibility in mutant cells, along with ChIP-seq of Smarcc1, Lsd1, and H3K4me1 in wild-type cells. g, Characterization of ATAC-seq in sites with unchanged accessibility in mutant cells, along with ChIP-seq of Smarcc1, Lsd1, and H3K4me1 in wild-type cells. h, Characterization of ATAC-seq in sites with increased accessibility in mutant cells, along with ChIP-seq of Smarcc1, Lsd1, and H3K4me1 in wild-type cells.
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additional examples in Supplementary Fig. 7 ). Accessibility at TSSs and enhancers was also broadly mirrored by altered ChIP read density of RNA polymerase II (RNAP2) ( Supplementary Fig. 8 ), suggesting that altered accessibility has functional importance for regulation of transcription.
To identify other chromatin features accompanying accessibility changes, we focused on three marks and factors: H3K4me1, RNAP2, and H3K27ac. We performed ChIP-seq for these factors in both wild-type and heterozygous (WT/G784E) mESCs to measure their changes at sites with altered accessibility. Despite significant correlation (R = 0.334, P < 2.22 × 10 -16 ), the effect size of altered H3K4me1 was low (m = 0.104), showing that sites with decreased accessibility generally maintained high levels of H3K4me1 (Fig. 5c ). RNAP2 also showed significant correlation (R = 0.230, P < 2.2 × 10 -16 ), with a modest effect size (m = 0.114). However, RNAP2 ChIP revealed that a small number of decreased sites also showed losses of RNAP2, suggesting that RNAP2 loading may only be affected when certain combinations of other changes occur ( Fig. 5d ). On the other hand, H3K27ac showed robust effects (R = 0.358, P < 2.2 × 10 -16 ) with a prominent effect size (m = 0.370), indicating a stronger relationship between H3K27ac and DNA accessibility ( Fig. 5e ). Hence, these sites transition from being 'active' enhancers (with high H3K27ac and high accessibility) to 'poised' enhancers (with maintained H3K4me1 but reduced H3K27ac and reduced accessibility).
Consistently, sites that lost accessibility (n = 2,692) had the highest levels of H3K27ac in wild-type cells (Fig. 5f ). In contrast, the sites that showed increased accessibility (n = 1,040) generally had lower levels of both H3K4me1 and H3K27ac in wild-type cells. Because most of these sites did not take on new elevated levels of H3K4me1 in mutant cells ( Fig. 5c ), we speculate that these sites may have taken on other unknown regulatory roles in mutant cells.
By exploring average accessibility changes over transcription factor sequence motifs, ATAC-seq permitted us to identify a set of transcription factors whose cognate sequences show reduced accessibility. One of these sequences was the combination motif for Oct4-Sox2-Tcf-Nanog, which undergoes an ~2-fold reduction of nucleosome-free ATAC-seq reads over the motif (Fig. 5g ). By scanning for reproducible changes, we obtained a list of 18 transcription factor motifs with recurrent losses of accessibility following expression of G784E SMARCA4 (Fig. 5h ). Our results show that mutant SMARCA4 induces alterations of the enhancer landscape, affecting a diverse set of factors rather than targeting a small subset of transcription factors. These changes in the enhancer network arise without expression of SMARCA2 (BRM, see Supplementary Fig. 9 ), allowing us to attribute our observations to SMARCA4 mutants.
Sites with lost accessibility in ES cells include hundreds of superenhancers from many tissue types.
In MRTs, loss of SMARCB1 affects active enhancers, but leaves superenhancers relatively protected 11 . We therefore sought to assess whether heterozygous SMARCA4 mutations would have similar effects. By classifying sites into genomic annotations for mESC TSSs, overall enhancers, or superenhancers, we found that superenhancers show distributions of accessibility changes comparable with those of overall enhancers (Fig. 5i) , both of which are significantly tilted toward losses compared to TSSs (P < 2.2 × 10 -16 ). Therefore, superenhancers are significantly impacted by heterozygous SMARCA4 mutation, unlike biallelic loss of SMARCB1. 
Fig. 5 | Heterozygous SMARCA4 mutation induces loss of accessibility and H3K27ac at active enhancers and superenhancers from many tissues. a, Mean ATAC-seq read density at TSSs and enhancers in wild-type and heterozygous mutant cells. b, Example genome track showing representative loss of accessibility and H3K27ac but preservation of H3K4me1 at an enhancer. c, Relationship between H3K4me1 ChIP and ATAC fold changes from wildtype and mutant cells with effect size (m). d, Relationship between RNAP2 ChIP and ATAC fold changes between wild-type and mutant cells with effect size. e, Relationship between H3K27ac
ChIP and ATAC fold changes between wild-type and mutant cells with effect size. P values were obtained using the Pearson product-moment correlation test. f, Abundance of H3K4me1 and H3K27ac in wild-type cells, classified by whether the site shows increased or decreased accessibility or was unchanged. Sites with decreased accessibility have elevated levels of H3K4me1 and H3K27ac, consistent with active enhancers. g, Mean accessibility changes at the Oct4-Sox2-Tcf-Nanog combination transcription factor motif. h, Heat map of 18 transcription factor motifs associated with reduced accessibility in heterozygous G784E SMARCA4 cells across n = 2 cell-culture replicates. i, Cumulative distribution of ATAC-seq fold change, classified by genomic annotation. j, Analysis of sites with decreased accessibility that overlap with superenhancers from multiple tissue types. Color in heat map shows fractional overlap with known annotated superenhancers from tissues obtained from dbSUPER. k, Distribution of the number of tissue types associated with each superenhancer site analyzed in j. l, Pie chart of the proportion of tissue-restricted superenhancers compared with superenhancers present in more than one tissue type. RPM, reads per million; Enh, enhancer; SE, superenhancer.
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Chromatin regulatory interactions in ES cells anticipate celltype-specific architecture that arises upon lineage commitment 51 . We therefore hypothesized that many sites we observed with reduced accessibility may correspond to sites with regulatory roles in differentiated cells. To assess whether affected sites correspond to important regulatory sites in multiple cell types, we examined overlap with an ensemble of annotated superenhancers across a variety of differentiated tissues, including those from lung, intestines, hematological, and neuronal lineages. By comparing to sites in the dbSUPER database of superenhancers 52 , we found that 940 sites (34.9% of decreased sites overall) are significantly enriched for direct overlap with previously annotated superenhancer sites from at least one tissue (Fig. 5j ,k, P < 2.2 × 10 -16 ). Plotting the distribution of associated tissue types for each superenhancer (Fig. 5l ) revealed that most of these sites (51.5%, 484 of 940) are superenhancers in more than a single tissue type. Therefore, heterozygous mutations of SMARCA4 induce accessibility losses at sites identified to have essential roles in maintaining cell identity across multiple tissue 
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types. Our findings furthermore show that BAF-dependent accessibility anticipates lineage specification in several lineages.
Effects on genomic accessibility are dominant negative. We next sought to investigate whether the observed changes reflected SMARCA4 haploinsufficiency or were instead a dominant-negative effect 53 . To measure the impact of loss from a single allele, we derived a line of mESCs for conditional deletion of only one allele of Smarca4. This actin-CreER;Smarca4 +/fl line expresses Cre recombinase fused to the estrogen receptor (CreER) and encodes a single floxed allele of Smarca4 and one wild-type allele. This permitted us to conditionally delete a single allele in the presence of 4-hydroxytamoxifen (Tam) and compare against mock treatment with ethanol (EtOH). Western blotting showed reduction of half of SMARCA4 protein levels (Fig. 6a,b) after tamoxifen-induced deletion. However, we did not observe reproducible changes in chromatin accessibility using ATAC-seq following the loss of the single allele, and only a single site met the criteria for a decreased site out of 41,267 ATAC-seq sites across the genome (Fig. 6c) . Notably, we did not detect changes at enhancers or TSSs as we observed for the ATPase mutants (Fig. 6d,e ). Importantly, our results leave open the possibility of changes at sites of lower accessibility or in other cell types or of other haploinsufficient roles (for example, in DNA repair).
In contrast to the loss of a single allele, G784E SMARCA4 resulted in accessibility losses that were correlated in their positions over the body of the chromosome (Fig. 6f ). Analysis of Hi-C data (Methods) permitted us to partition each chromosome into large multimegabase-scale compartments termed A and B compartments 54, 55 . We found that the more transcriptionally active A compartments tended to have more acute accessibility losses than the more repressed B compartments (Fig. 6f ). Focal accessibility changes within A compartments were significantly tilted toward losses compared to B compartments (Fig. 6g,h, P < 2.2 × 10 -16 ). Thus, enhancers in A compartments are differentially sensitive to the expression of ATPase mutant SMARCA4. However, these same sites are unaffected by loss of expression from a single allele of Smarca4. Therefore, the strong effects following heterozygous mutation of SMARCA4 ATPase reflect genetic dominance rather than haploinsufficiency. 
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Pro-oncogenic changes of gene expression include Polycomb and non-Polycomb targets.
To discover the effects of the altered enhancer landscape on transcription, we compared wild-type to heterozygous G784E SMARCA4 cells using RNA-seq. Despite the thousands of sites of altered accessibility described above, we found a modest set of changes to the transcriptional profiles of cells, with a small number of genes showing increased (n = 49) or decreased (n = 191) expression (criteria in Methods) (Fig. 7a ). Genes with changes included previously annotated Polycomb targets 56 (n = 86), which were significantly enriched among all altered genes (odds ratio = 1.74, P = 7.7 × 10 -5 ). We also observed altered expression of genes that are not Polycomb targets (n = 154; Fig. 7b ). Interestingly, despite reduced accessibility of their target sites, we did not observe loss of expression of the core pluripotency network, including Oct4 (Pou5f1), Sox2, Nanog, or Klf4. Expression of these factors was maintained or even enhanced in heterozygous mutant cells, as previously reported for complete knockout 45 . In contrast, we observed a significant ~2-fold increase in the expression of the proto-oncogene Myc (Fig. 7a,c ; log 2 fold change = 0.98, FDR-adjusted P = 0.01). Gene set enrichment analysis (GSEA) also revealed a significant enrichment of Myc target genes (FDRadjusted P < 2.2 × 10 -16 ), one of the hallmarks of many malignancies ( Fig. 7d ). Altogether, our results reveal that cell identity may be maintained through compensating mechanisms, despite a dramatic reshuffling of the enhancer and superenhancer landscape. In ES cells, these compensating mechanisms include upregulation of Myc, a hallmark of cancer that may be considered a pro-oncogenic response. Interestingly, biallelic deletion of SMARCA4 in the same cells leads to cell death 45 ; thus, dominant-negative mutations in cancer settings may similarly confer changes distinct from biallelic loss.
Discussion
Here we analyzed human tumor sequencing data to identify the major role played by heterozygous mutation of SMARCA4 (Fig. 1) . We analyzed the available mutation frequencies obtained through tumor sequencing studies in the context of structural models of SMARCA4 we derived from recent discoveries in structural biology [37] [38] [39] . By doing so, we discovered that frequently mutated positions of SMARCA4 lie on biologically significant surfaces ( Fig. 2a ). This clustering is consistent with earlier observations that mutations of key bioactive surfaces are significantly enriched across several cancer types 57 . These mutations induce characteristic dynamic defects, consistent with a model in which binding of SMARCA4 to DNA or nucleosomes promotes immobilization, and release from this immobile state is catalyzed by ATP hydrolysis (Fig. 2g) .
Despite divergent dynamic effects, mutations in either the ATP cleft or DNA groove give rise to similar changes across the chromatin landscape (Fig. 3) . The convergence of these defects indicates that cancer positively selects for functional inactivation rather than disruption of individual surfaces per se. Our results show that frequently occurring disease mutations inactivate SMARCA4 by diverse modes, for example, by impairing ATP hydrolysis, disrupting DNA binding, and likely other mechanisms. Our ATAC-seq results confirm that the effects of these mutations converge on the open chromatin landscape; we found consistent changes to DNA accessibility at thousands of sites over the genome, including at a large number of superenhancers from diverse cell types, regardless of how SMARCA4 was disrupted. In contrast to biallelic loss of other BAF subunits, which largely arise in lineage-restricted settings, heterozygous mutations of SMARCA4 contribute to malignancies from diverse tissue types. We propose that this broad pattern largely reflects disruption of the enhancer-accessibility landscape, including superenhancer sites used by many tissue types.
We found that a set of active enhancers in wild-type mESCs is particularly predisposed to lose accessibility (Fig. 5 ). These changes lead to losses of accessibility at an array of transcription factor motifs and concomitant losses of H3K27ac modification while, in most cases, preserving H3K4me1 levels. Hence, enhancer identity (as defined by H3K4me1 marking) is largely preserved, but active enhancers with high H3K27ac are particularly sensitive to SMARCA4 mutation affecting the ATPase domain. These effects are particularly pronounced in active A compartments, but do not arise upon loss of a single allele of Smarca4 (Fig. 5) , indicating dominantnegative effects for the missense mutants. Hence, we find that chromosomal organization heavily influences the dominant-negative effects of SMARCA4 disease mutants. Our data strongly suggest that in addition to its direct effects on PRC1 at bivalent genes 34 , SMARCA4 dynamically acts to generate accessibility in transcriptionally active compartments of the genome, notably at existing superenhancers and latent or primordial superenhancers.
Despite the thousands of changes in the open chromatin landscape, these alterations induce a relatively small number of significant transcriptional changes (Fig. 7a ). Altered genes include both Polycomb-target genes and non-Polycomb targets, indicating that regulation of the open chromatin landscape at enhancers constitutes a separate layer of regulation in addition to the mechanisms previously described for PRC1 (ref. 34 ). Of particular interest is the upregulation of the proto-oncogene Myc as well as its downstream targets (Fig. 7) . Myc enhances the stability of the pluripotency factors at their cognate sites on chromatin 58 and relieves transcriptional pausing 59, 60 . Therefore, it is appealing to speculate that heterozygous expression of mutant SMARCA4 in mESCs leads to loss of transcription factor accessibility or paused polymerases, and increased expression of Myc may compensate by stabilizing the interaction of transcription factors at their target sites or by relieving polymerase pausing following SMARCA4 mutation.
Altogether, our findings show that heterozygous SMARCA4 mutations induce loss of H3K27ac and accessibility at enhancers and superenhancers. Because ATP-cleft and DNA-groove mutants both induce these effects, we propose that SMARCA4's dominant-negative role at enhancers arises via sequestration of binding partners at unproductive transient binding sites or in the nucleoplasm (Fig. 7e ). Our results reveal that unlike biallelic loss of SMARCB1 or SMARCA4, heterozygous SMARCA4 missense mutations bias the epigenetic landscape by altering the accessibility of superenhancers used in a variety of different tissues. These changes permit the exploration of other sites in phenotypic space, which may promote pro-oncogenic changes of gene expression ( Fig. 7f) . Given our findings, additional studies in human models of cancer and neurologic disorders are warranted to fully test and examine the mechanisms we describe here. Taken together, the distinct effects of dominant-negative mutations suggest that therapeutic strategies targeting the large number of missense SMARCA4 mutations in cancer and neurologic disorders may require distinct approaches from those targeting biallelic inactivation.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41594-017-0007-3.
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Methods Culture of animal and human cells. Mouse ES cells used in this study were derived from 12-week-old B6;129 Sv pregnant female mice in the Crabtree lab following a published protocol 45 and authenticated by examination of morphology and expression of embryonic stem cell markers. These cells were cultured using standard conditions. Briefly, ES culture media containing DMEM (Cat# 10829018; Life Technologies), 15% FBS (Cat# ASM-5007; Applied StemCell), penicillin-streptomycin (Cat# 15140122; Life Technologies), Glutamax (Cat# 35050061; Life Technologies), HEPES buffer (Cat# 15630080; Life Technologies), 2-mercaptoethanol (Cat# 21985023; Life Technologies), MEM-NEA (Cat# 11140050; Life Technologies), and LIF supplement 61 was replaced daily, and ES cells were passaged every 48 h. For inducible deletions, Smarca4 fl/fl actin-CreER ES cells 45 and Smarca4 +/fl actin-CreER ES cells, which previously tested negative for mycoplasma contamination using PCR testing, were plated onto irradiated feeder mouse embryonic fibroblasts, treated with 0.8 uM Tam or EtOH for 48 h and harvested for further experiments after trypsin dissociation at 72 h.
Western blotting. Cells were lysed for at least 30 min at 4 °C in RIPA buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1% NP-40). Lysates were centrifuged for 30 min at 14,000 g, and the supernatant was flash frozen. The total protein concentration was measured by Bradford assay (Bio-Rad). We boiled 10 µ g of protein in gel loading buffer (Life Technologies) with 50 mM of dithiothreitol and loaded it onto 4-10% BisTris NuPage gels (Life Technologies). Bands were transferred to PVDF membranes (Bio-Rad), and then membranes were blocked in 5% BSA/TBST. Blots were then incubated with primary antibodies for 1 h at room temperature. Proteins were detected with the LI-COR detection system.
Construction and breeding of Smarca4-Dendra2 transgenic mice.
All studies involving laboratory animals were performed in accordance with animal welfare regulations established by the Stanford University Administrative Panel on Laboratory Animal Care (APLAC). All protocols used in this study were approved by the Stanford APLAC. Mutation was obtained using a targeting sequence derived from BAC clone bMQ-242m22 (Source Bioscience). The Dendra2 sequence was inserted using homologous recombination with a floxed neomycin resistance cassette. This resistance cassette was later excised by breeding to a mouse expressing ubiquitous Cre recombinase, leaving a single loxP site downstream of Dendra2. Validation of successful construction was performed with Southern and western blots, as well as fluorescence microscopy. For details regarding the construction of a Smarca4-Dendra2 fluorescent knock-in mouse, see Supplementary Fig. 2 . Embryonic stem cells expressing SMARCA4-Dendra2 were derived from 12-week-old B6;129 Sv pregnant female mice expressing the Dendra2 transgenic insertion immediately following the final exon of the Smarca4 gene. Heterozygotes were maintained by outbreeding to wild-type C57BL/6 (B6) mice. Homozygous mice were readily obtained by filial crossing of heterozygotes. Both heterozygotes and homozygotes lacked any detectable phenotype.
Genotyping of Smarca4-Dendra2 mice. Standard PCR conditions were used to genotype Smarca4-Dendra2 transgenic mice. PCR amplification conditions were as follows: 55 °C annealing temperature, 72 °C extension temperature for 30 s, 28 cycles. Wild-type alleles were specifically amplified using forward primer: CCC TAC CAT GGT GCA GGG CA and reverse primer: AAT GTC TGG TTC AGT CTT CCT CA to yield a 429-base pair (bp) amplicon product. Smarca4-Dendra2 alleles were specifically amplified using forward primer: GCC CAG CCA GGT GTG GTG AGC CCA ATT CCG ATC ATA TTC A and reverse primer: GGG CCT GTG AGC CTC CTG GA to yield a 469-bp amplicon product. Homozygous mice amplify only the wild-type or only the Smarca4-Dendra2 product, whereas heterozygous mice amplify both products.
Lentiviral preparation and infection.
Lentivirus was produced in Lenti-X 293 T cells (Clontech) via polyethylenimine transfection. Media were changed 24 h after transfection, and after another 48 h, media were collected and centrifuged for 2 h at 20,000 r.p.m. Viral pellets were resuspended in PBS and used to infect cells. Cells were selected with 2 μ g/ml puromycin, as appropriate beginning 48 h after infection.
Fluorescence recovery after photobleaching (FRAP). Cells were maintained at 37 °C under humidified 5% CO 2 using chambered µ -Dish 35-mm coverslips (Cat# 81156, Ibidi) in an enclosed inverted Leica SP2 laser scanning confocal microscope. Using Leica software, half of the nucleus of each cell was photobleached using 100 mW 405-nm laser excitation. Nuclear fluorescence was monitored as a time course, and each image was saved as a TIFF file. The degree of fluorescence recovery within the region of interest (ROI, the photobleached portion of the nucleus) was monitored within each image. Image masks were made using MATLAB to identify the full nucleus (visualized before photobleaching) and the ROI only. The ratio of fluorescence intensity within the ROI over the intensity throughout the entire nucleus was plotted and fit to exponential curves using nonlinear least square fitting, to obtain the recovery rate. Recovery half-lives derived from this fit were collected for each condition. P values to compare the populations of half-lives were obtained using the two-sample Kolmogorov-Smirnov (KS) test.
Deconvolution fluorescence microscopy. Deconvolution microscopy was performed on fixed cells using the OMX Blaze V4 microscope platform.
Assay of transposase-accessible chromatin (ATAC) library preparation.
ATAC libraries were independently prepared from separately cultured samples in duplicate, using methods previously described 46 . Briefly, we obtained nuclei by resuspending cells in 0.5 ml of lysis buffer (0.1% Tween-20 in RSB buffer) and incubated them for 10 min on ice. Nuclei were pelleted by centrifugation for 10 min at 500 g, resuspended in 50 μ l of transposition mix (1 × Tagmentation DNA buffer, 2.5 μ l Tagment DNA enzyme (Illumina)), and incubated for 30 min at 37 °C. DNA was purified with a MinElute PCR purification kit (Qiagen), and libraries were amplified by PCR with barcoded Nextera primers (Illumina). For sequencing, libraries were size selected with Agencourt AMPure XP (Beckman Coulter) for fragments between ~50 and 1,000 bp in length according to the manufacturer's instructions. Sequencing was performed using paired-end reads on the Illumina HiSeq2000 sequencer.
Processing of ATAC sequencing (ATAC-seq) data. Analysis of high-throughput sequencing data was not performed blindly, but the following techniques were applied uniformly to all datasets. Paired-end reads were processed by mapping to the mm9 reference mouse genome using Bowtie 2.1.0 (ref. 62 ). Duplicate fragments and reads with mapping quality < 10 were discarded, leaving only high-quality unique reads. For each fragment, two pseudofragments were generated, which occupied 200 bp centered at the true fragment ends. Peak calling was performed by MACS 2.1.1 (ref. 63 ) based on the density of pseudofragments.
For differential analysis, all peaks from control and treatment datasets within ± 1 kb were merged, and peaks below a threshold of 10 RPM in at least one dataset were discarded to remove low-quality peak calls. Background density of ATAC-seq signal was obtained by calculating the mean read density in the 100-bp window 8 kb away from each peak. This background density was subtracted from the overall read density within each peak in each dataset. For each dataset, the total number of background-adjusted reads overlapping each of the resulting peaks was compared for differential peak calling. Differential peak calls were made using DESeq2 (ref. 64 ), using the summed number of background-adjusted reads at the top 5% of highest read-density sites as size factors. DESeq2 accounts for individual site variances across all replicates to make differential peak calls. Log 2 fold changes were calculated by the default use of maximum a posteriori estimation using a zero-mean normal prior (Tikhonov-Ridge regularization). FDR-corrected P values were calculated using the Benjamini-Hochberg procedure. Differential calls were made by requiring fold changes of > 1.5-fold in either direction and FDR-corrected P < 0.10. RPM values in genome tracks are the mean values across both replicates from each condition. Mean density profiles were computed using bwtool 65 by calculating the mean bp coverage across all replicates for a given condition. Overlap of peaks was performed using Bedtools 66 .
Chromatin immunoprecipitation sequencing (ChIP-seq) library preparation.
ChIP libraries were independently prepared from separately cultured samples in duplicate, according to previously described protocols [67] [68] [69] . Briefly, we fixed 10-30 million cells in suspension for 15 min in 1% formaldehyde. Excess formaldehyde was quenched by the addition of glycine to 100 mM. Fixed cells were washed, pelleted, and flash frozen. Pellets were thawed, resuspended in NP Rinse 1 buffer (50 mM HEPES-KOH, pH 8.0, 140 mM NaCl, 1 mM EDTA, pH 8.0, 10% glycerol, 0.5% NP-40, 0.25% Triton X-100) and incubated for 10 min on ice to isolate nuclei. Nuclei were washed once with NP Rinse 2 buffer (10 mM Tris-HCl, pH 8.0, 1 mM EDTA, pH 8.0, 0.5 mM EGTA, pH 8.0, 200 mM NaCl) and then twice with shearing buffer (0.1% SDS, 1 mM EDTA, pH 8.0, 10 mM Tris-HCl, pH 8.0). Pellets were resuspended in 900 µ l of shearing buffer with protease inhibitors and sonicated in a Covaris E220 sonicator for 10-12 min to generate DNA fragments between ~200 and 1,000 bp in length. Chromatin was then immunoprecipitated overnight at 4 °C with antibodies bound to Protein G Dynabeads. (Life Technologies) in ChIP buffer (50 mM HEPES-KOH, pH 7.5, 300 mM NaCl, 1 mM EDTA, pH 8.0, 1% Triton X-100, 0.1% DOC, 0.1% SDS). The chromatin-bead slurry was washed with a magnetic rack four times with ChIP buffer, once with DOC buffer (10 mM Tris-HCl, pH 8.0, 250 mM LiCl, 0.5% NP-40, 0.5% DOC, 1 mM EDTA, pH 8.0), and once with TE buffer. Chromatin was eluted with Q7 elution solution (0.1 M NaHCO3, 1% SDS). After RNase A (Life Technologies) and proteinase K (New England BioLabs) digestion and de-crosslinking at 65 °C overnight, DNA was extracted with phenol-chloroform and precipitated with ethanol. Size selection was performed by extracting 200-400-bp DNA fragments on a 2% agarose E-gel (Invitrogen) before PCR amplification, then extracted using MinElute cleanup kits (Qiagen). PCR amplification was performed using ≤ 14 cycles, and the resulting DNA quantified by Qubit fluorometric quantitation. Sequencing was performed using single-end reads on the Illumina HiSeq2000 sequencer. Antibodies used in these studies include rabbit anti-H3K4me1 (Abcam, Cat# ab8895, Lot number: GR251663-1), rabbit anti-H3K27ac (Abcam, Cat# ab4729, Lot number: GR104852-1), and mouse monoclonal anti-RNAP2 (Covance clone 8WG16, Cat# MMS-126R).
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Experimental design 1. Sample size
Describe how sample size was determined. All high-throughput sequencing assays were performed in duplicate using independent biological (cell culture) samples. All mutants were selected in advance. For all assays, sample size was decided in advance, and uniform.
Data exclusions
Describe any data exclusions. no data was excluded from study
Replication
Describe whether the experimental findings were reliably reproduced.
For all high-throughput sequencing, replication was performed and reliability assessed in Figure S6 .
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Experimental groups were selected based on the individual genetic variant of Smarca4 being studied in each condition (i.e. WT, or individual mutants). Replicates of each condition were pooled for analysis.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Data sets were not analyzed blindly, but were all processed according to uniform, identical processing steps.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
